Unique ID issued by UMIN | UMIN000017694 |
---|---|
Receipt number | R000020429 |
Scientific Title | Efficacy of neoadjuvant chemoradiotherapy with Metformin for locally advanced pancreatic cancer |
Date of disclosure of the study information | 2015/05/28 |
Last modified on | 2022/12/12 17:47:39 |
Efficacy of neoadjuvant chemoradiotherapy with Metformin for locally advanced pancreatic cancer
PK-NACRT-Gmet
Efficacy of neoadjuvant chemoradiotherapy with Metformin for locally advanced pancreatic cancer
PK-NACRT-Gmet
Japan |
pancreatic cancer
Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery | Radiology |
Malignancy
NO
To evaluate the anticancer effect of neoadjuvant chemoradiotherapy using gemcitabine with metformin for locally advanced pancreatic cancer.
Efficacy
the ratio of histological remnant cancer cells
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine | Other |
Duration: 3 months
Dose
Neoadjuvant chemoradiation: Gemcitabine(150mg/m2/w)+RT(50.4G/28f)
Metformin: from 5days before starting neoadjuvant chemoradiation until surgery.(1500mg/3x)
20 | years-old | <= |
80 | years-old | >= |
Male and Female
1) Certification of pancreatic cancer (histological confirmation is desired).
2) Beyond borderline resectable pancreatic cancer (NCCN guideline 2013 ver.1).
3) No prior anti-tumor therapy for pancreatic cancer.
4) Patient age: over 20 years old, 80 years old or less.
5) Performance status (ECOG) is 0 or 1.
6) Essential organ function is preserved.
WBC counts: over 3000/mm3
Neutrophil counts: over 2000/mm3
Platelets counts: over10^4/mm3
Hb: over 9 g/dl
TBil: below 3.0 mg/dl
AST/ALT: 5 times less than the upper limit of normal
Serum creatinine: below 1.3mg/dl (male) 1.2mg/dl (female)
7) Patients with type 2 diabetes
8) Written consent has been obtained from the patient himself.
1) Pulmonary fibrosis or interstitial pneumonia
2) severe infectious disease
3) Patients with uncontrolled heart failure , angina, arrhythmias, and myocardial infarction within 6 months after the onset.
4) uncontrolled diabetes
5) Patients with active infection
6) Patients with pregnant women, the possibility or intention of lactating and pregnant.
7)severe drug allergy
8)peptic ulcer and bleeding
9)obvious neurological disorder or mental disorder
10)active double cancer
11)Patients who are already administered metformin
12)other severe complications
13)The patients who are judged inadequate to the present study by Principal investigator or researcher.
40
1st name | Akinobu |
Middle name | |
Last name | Taketomi |
Hokkaido University Graduate School of Medicine
Gastroenterological Surgery 1
060-8638
N15, W-7, Kita-ku Sapporo Japan
011-706-5927
taketomi@med.hokudai.ac.jp
1st name | Tatsuhiko |
Middle name | |
Last name | Kakisaka |
Hokkaido University Hospital
Gastroenterological Surgery 1
060-8638
N15, W-7, Kita-ku Sapporo Japan
011-706-5927
kakisaka@pop.med.hokudai.ac.jp
Hokkaido University Graduate School of Medicine Gastroenterological Surgery 1
Hokkaido University Graduate School of Medicine Gastroenterological Surgery 1
Self funding
Hokkaido University Hospital Division of Clinical Research Administration
Kita 14, Nishi 5, Kita-ku, Sapporo, Hokkaido, 060-8648 Japan
011-701-7636
crjimu@huhp.hokudai.ac.jp
NO
北海道大学病院(北海道)
2015 | Year | 05 | Month | 28 | Day |
Unpublished
Enrolling by invitation
2015 | Year | 05 | Month | 25 | Day |
2015 | Year | 05 | Month | 14 | Day |
2015 | Year | 06 | Month | 18 | Day |
2025 | Year | 12 | Month | 01 | Day |
2015 | Year | 05 | Month | 27 | Day |
2022 | Year | 12 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020429
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |